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Background: Metabotropic glutamate receptor 4 (mGluR4) and dopamine D2 receptors are specifically
expressed within the indirect pathway neurons of the striato-pallidal-subthalamic pathway. This unique
expression profile suggests that mGluR4 and D2 receptors may play a cooperative role in the regulation
and inhibitory control of behaviour. We investigated this possibility by testing the effects of a
functionally-characterised positive allosteric mGluR4 modulator, 4-((E)-styryl)-pyrimidin-2-ylamine
(Cpd11), both alone and in combination with the D2 receptor antagonist eticlopride, on two distinct
forms of impulsivity.
Methods: Rats were trained on the five-choice serial reaction time task (5-CSRTT) of sustained visual
attention and segregated according to low, mid, and high levels of motor impulsivity (LI, MI and HI,
respectively), with unscreened rats used as an additional control group. A separate group of rats was
trained on a delay discounting task (DDT) to assess choice impulsivity.
Results: Systemic administration of Cpd11 dose-dependently increased motor impulsivity and impaired
attentional accuracy on the 5-CSRTT in all groups tested. Eticlopride selectively attenuated the increase in
impulsivity induced by Cpd11, but not the accompanying attentional impairment, at doses that had no
significant effect on behavioural performance when administered alone. Cpd11 also decreased choice
impulsivity on the DDT (i.e. increased preference for the large, delayed reward) and decreased locomotor
activity.
Conclusions: These findings demonstrate that mGluR4s, in conjunction with D2 receptors, affect motor-
and choice-based measures of impulsivity, and therefore may be novel targets to modulate impulsive
behaviour associated with a number of neuropsychiatric syndromes.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Maladaptive impulsivity, the tendency to act prematurelyhate; CSF, cerebrospinal fluid;
ration at 30%; EC50, effective
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ry post-synaptic current; LH,
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im.com (A. Pekcec).
Ltd. This is an open access article uwithout foresight, is a multi-faceted behavioural trait associated
with impaired response inhibition and a preference for instant
gratification (Robbins and Dalley, 2016). Impulsive behaviour is a
core feature of attention-deficit/hyperactivity disorder (Castellanos
et al., 2006) and drug addiction (de Wit, 2009; Hester and Garavan,
2004; Lee et al., 2009; Moeller et al., 2001), and is thought to
manifest from abnormalities in a distributed network of brain re-
gions centred on the prefrontal cortex (PFC), hippocampus, and
basal ganglia (Baunez and Robbins, 1997; Dalley et al., 2011; Jentsch
and Taylor, 1999; Rieger et al., 2003;Winstanley et al., 2006). Motor
and choice impulsivity represent two neurobiologically-
dissociable, yet potentially overlapping forms of ‘waiting impul-
sivity’ e defined as an intolerance for delayed rewards and annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Mean plasma and CSF concentrations of Cpd11 measured 45 min after drug
administration (±SEM). Mean plasma concentrations of eticlopride measured
35 min after drug administration (±SEM).
Mean Plasma
Concentration (nM)
Mean CSF
Concentration (nM)
Cpd11
(mg/kg; p.o.; n ¼ 4)
60 17950 ± 2.96 1562.3 ± 299.71
80 20000 ± 1.42 1715 ± 312.89
Eticlopride (mg/kg; s.c.; n ¼ 4)
0.005 0.78 ± 0.23 e
0.01 1.57 ± 0.83 e
0.02 3.51 ± 0.69 e
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260250inability to refrain from responding during delays signalling future
reward (Dalley et al., 2011; Robinson et al., 2009).
Glutamate is the principal excitatory neurotransmitter within
the mammalian central nervous system and acts via two distinct
receptor sub-types; ionotropic (iGluR) and metabotropic (mGluR)
glutamate receptors (Conn and Pin, 1997; Schoepp, 2001). Based on
distinct neuroanatomical distributions and functional dissocia-
tions, as well as the increasing availability of selective allosteric
modulators, mGluRs may provide novel targets for therapeutic
intervention in a number of neuropsychiatric disorders (Conn and
Pin, 1997; Nakanishi, 1992; Schoepp and Conn, 2002). Metabo-
tropic glutamate receptor 4 (mGluR4) is a group III, inhibitory
mGluR expressed pre-synaptically within both the ventral and
dorsal divisions of the striatum and pallidum (Bradley et al., 1999;
Corti et al., 2002), specifically at cortico-striatal glutamatergic and
striato-pallidal GABA-ergic synapses (Beurrier et al., 2009; Bradley
et al., 1999; Cuomo et al., 2009; Gubellini et al., 2014). Thus mGluR4
is ideally located to modulate the D2 receptor-expressing indirect
pathway (Bradley et al., 1999) projecting from the striatum to the
pallidum and subsequently the subthalamic nucleus (STN; Albin
et al., 1989; DeLong, 1990; Missale et al., 1998; Smith et al., 1998).
Functionally, mGluR4 activation suppresses glutamatergic and
GABA-ergic neurotransmission in the striatum and globus pallidus
(GP), respectively (Beurrier et al., 2009; Cuomo et al., 2009;
Gubellini et al., 2014; Pisani et al., 1997; Valenti et al., 2003).
In the present study, we investigated the effects of positive
allosteric mGluR4 modulation on motor and choice impulsivity.
Following functional characterisation in vitro, we assessed the ef-
fects of a selective positive allosteric mGluR4 modulator 4-((E)-
styryl)-pyrimidin-2-ylamine (Cpd11; East et al., 2010), on prema-
ture responding on the 5-CSRTT (Robbins, 2002). To reveal a pu-
tative involvement of the D2 receptors, we investigated the effects
of administering the D2 receptor antagonist eticlopride alone and in
combination with Cpd11 on 5-CSRTT performance. We subse-
quently assessed the effects of sub-chronically administered Cpd11
to reveal possible compensatory effects on different aspects of
performance in the 5-CSRTT. For comparative purposes, we also
assessed the effects of Cpd11 on choice impulsivity using the delay
discounting task (DDT).
2. Material and methods
2.1. Subjects
Male Lister-hooded rats (Charles River, Germany), weighing
250e280 g, were trained and assessed for performance on the 5-
CSRTT and DDT. A separate group of Lister-hooded rats, weighing
250e300 g (Charles River, Germany), were used for the assess-
ment of locomotor activity. All rats were housed in groups of four
under a 12 h light/dark cycle with food and water initially
available ad libitum. Food restriction was initiated in the trained
rats when body weights were at least 300 g. Animals were pro-
vided with environmental enrichment, consisting of red Perspex
tunnels and wooden gnawing blocks. Body weight was then
maintained at approximately 85% of free feeding weight. All
training and testing commenced between the hours of 07:00 and
15:00, five days a week. All experimental procedures were
authorised by the Local Animal Care and Use Committee in
accordance with local animal care guidelines, AAALAC regula-
tions and the USDA Animal Welfare Act.
2.2. Drugs
Cpd11 was synthesised at Boehringer Ingelheim, Germany. For
the functional characterisation experiments conducted in vitro,Cpd11 was dissolved in 100% DMSO at a stock concentration of
10 mM and stored at 20 C. For the in vivo studies, all drugs were
administered according to a Latin square design unless otherwise
stated. Cpd11 was dissolved in 10% Tween80 (0.1% v/v) and 90%
Natrosol (0.5%) and administered orally (p.o.) at 2 ml/kg, 30 min
before testing. Eticlopride hydrochloride was purchased from
Sigma Aldrich (Germany), dissolved in saline (0.9%) and adminis-
tered subcutaneously (s.c.), at 1 ml/kg, 20 min before testing. D-
amphetamine was purchased from Sigma Aldrich (Germany), dis-
solved in saline (0.9%) and administered intraperitoneally (i.p.),
2 ml/kg, 15 min before testing. Drugs that were administered i.p. or
s.c. were adjusted to pH 7.4.
The selected dose ranges and pre-treatment times for Cpd11 and
eticlopride were based on initial pharmacokinetic studies and
preliminary behavioural experiments conducted in house (East
et al., 2010). For example, 30 min following administration of a
30 mg/kg dose of Cpd11, plasma and CSF concentrations of 11.6 mM
and 0.7 mM were measured (CSF:plasma ~0.06). In vitro, an EC50 of
~1 mM was calculated for Cpd11. Based on these findings, it was
necessary to select a dose range sufficient to produce CSF exposures
in line with this value. In preliminary behavioural experiments,
30 mg/kg Cpd11 failed to modulate 5-CSRTT performance, indi-
cating a minimum effective dose of approximately 40 mg/kg (based
on the estimated CSF:plasma ratio and in vitro data). A maximal
dose of 80 mg/kg was chosen to ensure high selectivity towards
mGluR4; Cpd11 has shown to exert mGluR5 modulation activity at
high concentrations (IC50 ~ 10 mM) (East et al., 2010). To confirm
suitable drug exposures were attained in the behavioural studies,
plasma exposures for Cpd11 and eticlopride were assessed using
satellite rats (Table 1). CSF exposures for Cpd11 were also assessed
and compared to the EC50 values calculated in vitro.
2.3. Compound characterisation e cAMP assay
The functional and allosteric properties of Cpd11 were assessed
in vitro using the LANCE® Ultra cAMP assay kit (Perkin Elmer, USA)
for the determination of changes in intracellular cAMP via Gi-
coupled receptor modulation. The protocol was based on that
provided by Perkin Elmer and is described in detail in the
supplementary material (S1).
2.4. Behavioural measures
2.4.1. Five-choice serial reaction time task training
Thirty-two operant chambers (Med Associates Inc, St. Albans,
Vermont) were used, as described previously (Bari et al., 2008; Carli
et al., 1983). Each chamber consisted of five evenly-spaced aper-
tures containing an LED light, set into a curved wall at the rear of
the chamber. A centrally-located food magazine was located on the
opposite wall, into which 45 mg reward pellets could be delivered
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260 251(Sandown Scientific, UK). Infrared beams located at the entrance of
each aperture and the food magazine allowed detection of nose
pokes.
The 5-CSRTT training protocol has been described previously
(Isherwood et al., 2015). Briefly, 96 rats were habituated to the
behavioural apparatus for three days, with gradual food restriction
being initiated three days prior. Each training session consisted of
100 trials and lasted no longer than 30 min. Training sessions
started with the illumination of the house and magazine light, and
by the delivery of a reward pellet. Reward collection initiated the
first trial. A single trial consisted of an inter-trial interval (ITI), fol-
lowed by the pseudo-random illumination of one of the five aper-
tures for a fixed duration (stimulus duration; SD). Following
stimulus onset, a nose-poke to the corresponding aperture, within
a fixed time interval (limited hold; LH) was required for reward
delivery. Premature responses made during the ITI, incorrect re-
sponses and responses made outside the LH (an omission) resulted
in a timeout (TO), during which time no food was delivered and the
house light was extinguished for 5 s. Animals were trained for at
least 1 week before starting each drug study; performance was
deemed stable when they consistently completed 100 trials with
70% accuracy and25% omissions (SD 0.7 s; ITI 5 s; LH 5 s). At this
stage, perseverative responses resulted in a 5 s TO and loss of food
reward. A SD of 0.7 s was used rather than 0.5 s (e.g. Carli et al.,
1983) to compensate for the less-bright light emitting diodes
(LEDs) present in Med Associates boxes. On the day before each
drug challenge, a baseline session was run to ensure that perfor-
mance did not drift during the course of the experiment.
Premature responding was calculated as a percentage of
completed trials (correct þ incorrect þ omissions). A premature
response was deemed an incomplete trial and re-set the current
trial. Percentage accuracy was defined as the number of correct
responses divided by the sum of correct and incorrect responses.
Perseverationwas calculated as the number of additional responses
made in the same aperture, following a correct response. Omissions
were calculated in terms of the percentage of completed trials.
2.4.2. Impulsivity screening
Based on neurobiological differences that exist between trait
high- and low-impulsive rats assessed on the 5-CSRTT (e.g.
Caprioli et al., 2014; Dalley et al., 2007; Jupp et al., 2013; Zeeb
et al., 2016), it was hypothesised that modulating impulsivity via
pharmacological mechanisms that target mGluR4 may produce
differential effects on motor impulsivity that depend on dopa-
minergic mechanisms (Besson et al., 2010; Fernando et al., 2012;
Moreno et al., 2013). Thus, the motor impulsivity studies were
conducted in rats selected for high-, mid- and low-levels of trait
impulsivity. Due to the limited effect of positive allosteric mGluR4
modulation on DDT performance, no such screening took place for
this behavioural task.
Screening for impulsivity consisted of four ‘challenge’ training
sessions where the ITI was extended to 7 s to increase the occur-
rence of premature responses (Dalley et al., 2007). Each challenge
session was separated by four baseline training sessions, where
task parameters were restored to the training configuration. The
mean percentage of premature responses made by each rat across
the challenge sessions was calculated. Rats were excluded from the
study if they exhibited poor or unstable performance or failed to
complete 100 trials on the majority of challenge sessions. Of the 96
rats trained, 16 rats were excluded in this way. All rats were ranked,
based on the mean % premature responses, from highly-impulsive
to low-impulsive. The upper and lower 15th centiles of prema-
ture responders were termed high-impulsive (HI) and low-
impulsive (LI) rats, respectively. The remaining rats were cat-
egorised as mid-impulsive (MI).2.4.3. Delay discounting task
Thirty-two operant chambers were used (Med Associates Inc, St.
Albans, Vermont), as described previously (Mar and Robbins, 2007;
Winstanley et al., 2003). Each chamber consisted of two retractable
levers located on either side of a centrally-located food magazine
into which reward pellets could be delivered (Sandown Scientific,
UK). A stimulus light was located above each lever and an infrared
beam at the entrance of the food magazine detected reward
collection. Rats were habituated to the behavioural apparatus for
three days under a fixed ratio-1 schedule of reinforcement before
starting pre-training. See the supplementary material (S2) for de-
tails on habituation and pre-training.
During DDT training, each session consisted of 6 blocks of 10
trials, with each trial lasting 72 s. Each block began with four
forced-choice trials whereby the left and right levers were each
presented twice in a random order. Responding on the right lever
resulted in the immediate delivery of a single reward pellet.
Responding on the left lever resulted in the delayed delivery of
three reward pellets, with increasing delay across blocks from 0 s
(block 1), 2 s (block 2), 4 s (block 3), 8 s (block 4), 16 s (block 5) and
32 s (block 6). Following the completion of four forced trials, six
free-choice trials were introduced. As in the pre-training protocol,
each trial was initiated by the illumination of the house and
magazine lights. Rats were required to nose poke the food maga-
zine within 10 s to trigger the presentation of both levers and lever
lights. A failure to respond on either lever within 10 s (omission)
resulted in the retraction of both levers with all lights extinguished
and an ITI initiated before the next trial. Responding on one of the
levers within 10 s resulted in the retraction of both levers and all
lights being extinguished. Reward delivery was preceded by the
illumination of the magazine light either immediately or after the
chosen delay. The length of the ITI was dependent on the choice of
the immediate or delayed lever, and followed reward delivery to
ensure each trial was exactly 72 s in duration. Task parameters and
data collection for the 5-CSRTT and DDT were controlled by Med
Associates Inc. software (St. Albans, Vermont).
2.4.4. Locomotor activity
Locomotor activity was assessed using eight Tru Scan arena
chambers measuring 39  41  41 cm, equipped with two sensing
rings (Couldbourn Instruments, USA) to detect activity along three
orthogonal planes; mean distance travelled (cm), total rearing
events, and rearing time (sec). All rats were habituated in an annexe
to the experimental room before testing.
2.5. Experimental design
2.5.1. Experiment 1: effect of mGluR4 modulation and D2 receptor
antagonism on 5-CSRTT performance
Rats which had either not undergone impulsivity screening
(unscreened rats; n ¼ 10) or those selected for high and low levels
of impulsivity (n ¼ 12 per group) were used to assess the effect of
systemic Cpd11 administration on 5-CSRTT performance. Rats
received vehicle, 40, 60 and 80 mg/kg Cpd11 and were tested
30 min later.
Mid-impulsive rats were used to assess the interactive effect of
D2 receptor antagonism and positive allosteric mGluR4 modulation
on 5-CSRTT performance. Initially, 12 rats were used to assess the
systemic effects of eticlopride when administered alone; rats
received vehicle, 0.005, 0.01 and 0.02 mg/kg eticlopride and were
tested 20 min later. Subsequently, 16 rats were used to investigate
the interactive effects of 60 mg/kg Cpd11 and eticlopride treatment
(0.05 and 0.01 mg/kg). Cpd11 was administered 30 min before
behavioural testing, as before, followed by the administration of
eticlopride 10 min later.
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CSRTT performance in MI rats
Nineteen MI rats were used to investigate the effects of sub-
chronic Cpd11 treatment on 5-CSRTT performance. Following two
pre-treatment baseline test sessions, rats were divided into two
groups matched for levels of premature responding. For five sub-
sequent days, rats were administered Cpd11 (80 mg/kg), or vehicle,
and tested on the 5-CSRTT 30min later. To investigatewhether sub-
chronic Cpd11 treatment resulted in longer-lasting effects on 5-
CSRTT performance, behaviour was assessed for an additional
two days immediately following treatment termination (post-
treatment baseline).
2.5.3. Experiment 3: effect of positive allosteric mGluR4 modulation
on DDT performance
Rats that were trained on the DDT were used to assess the ef-
fects of systemic Cpd11 treatment on choice performance (n ¼ 15).
Cpd11 was administered at 40, 60 and 80 mg/kg, 30 min before the
task. As a positive control, all rats also received d-amphetamine
(0.5 mg/kg) 15 min before the task to ensure the DDT was suffi-
ciently sensitive to detect changes in choice performance.
2.5.4. Experiment 4: effect of positive allosteric mGluR4 modulation
on locomotor activity
Thirty-two untrained rats were assessed for locomotor activity
following systemic Cpd11 administration. Using a between-
subjects design, rats received 40, 60 or 80 mg/kg Cpd11, or
vehicle, during the habituation period. Thirty minutes later, rats
were placed into the locomotor activity chambers and permitted
free exploration for 30 min.
A summary of experimental groups and group sizes for each
experiment conducted in this study is shown in Table 2. Group
sizes of 12 for the 5-CSRTT and 8 for the locomotor studies were
chosen based on previous experiments (Isherwood et al., 2015). As
HI and LI rats were selected from the extremes of the distribution,
a group of MI rats (n ¼ 16) was also available for the pharmaco-
logical interaction study. Given the relatively high individual
variability in DDT performance, a larger group size (n ¼ 15) was
used to investigate the effects of Cpd11 on delay discounting
impulsivity.
2.6. Statistical analysis
All analyses were conducted using SPSS for Windows (version
21) and GraphPad Prism 6. Behavioural data were analysed by
analysis of variance (ANOVA). Statistical significance was set at
p < 0.05. In the case of a violation of sphericity, as shown by a
significant main effect in Mauchly's test of sphericity, the
Greenhouse-Geisser correction (GG ε) was used to adjust the de-
grees of freedom for correction of p values. Behavioural data on the
5-CSRTT were analysed using repeated measures ANOVA. In theTable 2
Experimental groups, impulsivity groups and group sizes.
Study Drug administration Experimental groups
5-CSRTT Cpd11 3 experimental groups þ contro
Eticlopride 3 experimental groups þ contro
Cpd11 þ Eticlopride 3 experimental groups þ contro
Sub-chronic Cpd11 1 experimental group þ control
DDT Cpd11 3 experimental groups þ contro
Locomotor Cpd11 3 experimental groups þ contro
HI, high-impulsive; MI, mid-impulsive; LI, low-impulsive; US, unscreened; UT, untrainedstudy involving HI, LI and unscreened rats, impulsivity group and
drug dose served as between- and within-subject factors, respec-
tively. In studies involving MI rats, drug dose served as a within-
subjects factor. Where significant main effects or interactions
were observed, further analysis using Dunnett's or Bonferroni post
hoc tests was performed. In the study involving a sub-chronic
treating regime, drug and treatment day served as between- and
within-subject factors, respectively. Planned comparisons, using
the Bonferroni correction, were performed here. DDT data were
analysed using repeated measures ANOVA with both delay and
drug dose serving as within-subject factors, followed by Fisher's
least significant difference (LSD) post hoc test where indicated by a
significant delay  dose interaction. Locomotor activity data were
analysed using one-way ANOVA followed by Dunnett's post hoc test
where indicated by a significant main effect of drug dose (between-
subjects factor).3. Results
3.1. Compound characterisation e cAMP assay
Cells over-expressing mGluR4 exhibited concentration-
dependent increases in intracellular cAMP production following
forskolin stimulation (Fig. 1A). A concentration of 1.2 mM forskolin
was selected to stimulate the cells in all further experiments.
Glutamate attenuated the effect of forskolin stimulation on cAMP
production with an EC50 of 54.08 ± 0.04 mM (Fig. 1B). The concen-
tration of glutamate necessary to evoke approximately 30% of the
maximal glutamate response (EC30) was determined (30 mM) and
subsequently used in the allosteric modulation experiments.
Positive allosteric mGluR4 modulation, by Cpd11,
concentration-dependently potentiated the effects of 30 mM
glutamate on intracellular cAMP production with an EC50 of
1.46± 0.05 mM. However, Cpd11 failed to elicit a significant effect on
cAMP production in the absence of glutamate (Fig. 1C). Increasing
concentrations of Cpd11 evoked parallel, leftward shifts of the
glutamate concentration-response curve (Fig. 1D); shifting the
glutamate EC50 approximately 20 fold (maximal shift
factor ¼ 20.02), thus indicating enhanced potency of glutamate at
mGluR4 by Cpd11 application. These results provide strong evi-
dence for allosteric modulation of mGluR4 by Cpd11. The subtle
effect observed in the absence of glutamate and the slight down-
ward shift of the glutamate concentration-curve may imply some
agonistic properties of Cpd11. However, this effect was minimal and
was only seen at the highest concentrations (approximately 10 fold
higher than the EC50). A similar pharmacological profile has been
reported previously (East et al., 2010).
Consistent with these data, Cpd11 administered at 60 and
80mg/kg reached plasma concentrations of 17.9 and 20 mMand CSF
concentrations (i.e. free-fraction) of 1.56 and 1.72 mM, respectively,
45 min after drug administration (Table 1). These values areImpulsivity groups Group size
l HI, LI and US n ¼ 10/12
per group
l MI n ¼ 12
l MI n ¼ 16
MI n ¼ 9/10 per group
l þ positive control US n ¼ 15
l UT n ¼ 8
per group
.
Fig. 1. Functional response of mGluR4-expressing cells to varying concentrations of forskolin, glutamate and Cpd11. (A) Forskolin concentration-response curve. (B) Glutamate
concentration-response curve in the presence of 1.2 mM forskolin. (C) Cpd11 concentration-response curve in the presence of 1.2 mM forskolin and 0 or 30 mM glutamate. (D)
Concentration-dependent leftward shift of the glutamate concentration-response curve by Cpd11. Compound concentration-response curves were generated from triplicates of a
single experiment and are expressed as mean ± SD. Raw data were normalised to a cAMP standard (E).
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260 253perfectly in line with those reported previously (East et al., 2010),
and with the EC50 value measured for Cpd11 in vitro. This is
important because, although Cpd11 shows high selectivity towards
mGluR4 (limited activity on a panel of 68 other targets), it has
shown to exhibit some negative allosteric modulation activity at
mGluR5. However, the window between mGluR5 and mGluR4 ac-
tivity is approximately 10-fold (East et al., 2010); exposures which
are not achieved with the given systemic doses. Together, these
findings confirm that Cpd11 exerts positive allosteric activity over
mGluR4 in vitro and that the selected dose ranges are sufficient to
exert a pharmacological effect in vivo.3.2. Experiment 1: effect of mGluR4 modulation and D2 receptor
antagonism on 5-CSRTT performance
Fig. 2 shows the effects of systemic Cpd11 administration on 5-
CSRTT performance in HI and LI rats and those unscreened for
impulsivity. Cpd11 dose-dependently increased premature
responding (Fig. 2A; main effect of dose, F3,31 ¼9.25, p < 0.001) and
decreased attentional accuracy (Fig. 2B; main effect of dose,
F3,23 ¼ 23.7, p < 0.001). These effects were independent of impul-
sivity group and were present for all doses of Cpd11 tested (pre-
mature: 40 mg/kg, p < 0.01; 60e80 mg/kg, p < 0.001 and accuracy:
Fig. 2. Effect of Cpd11 on 5-CSRTT performance in HI (n ¼ 12), LI (n ¼ 12) and unscreened (n ¼ 10) rats: (A) percent premature responses, (B) percent accuracy, (C) perseverative
responses, (D) percent omissions, (E) correct response latency and (F) reward latency. Bars represent mean ± SEM. Repeated measures ANOVA (mixed design), ##p < 0.01 main
effect of group; Dunnett's post hoc test, ¥¥ p < 0.01, ¥¥¥ p < 0.001 HI, LI and unscreened (combined) verses vehicle control.
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effect on perseverative responding (main effect of dose, F2,71¼4.08,
p < 0.05, X2 ¼ 12.94, GG ε ¼ 0.76), however this failed to reach
statistical significance for any single dose (Fig. 2C). Although
omissions and correct response latencies were unaffected by Cpd11
treatment (Fig. 2D and E), these measures were consistently
reduced in HI rats (omissions and correct latency: main effect of
group, F2,31¼5.51, p < 0.01 and F2,31¼6.49, p < 0.001, respectively).
Post hoc analysis revealed that whereas omissions were reduced in
HI rats compared with both LI and unscreened rats (p < 0.01 and
p < 0.05, respectively) correct response latencies were reduced in
HI rats compared with LI rats (p < 0.01). Reward latencies were also
unaffected by Cpd11 treatment (Fig. 2F), however these were
consistently increased in unscreened rats (main effect of group,
F2,31 ¼ 5.75, p < 0.01, X2 ¼ 14.32, GG ε ¼ 0.82) compared with HI
(p < 0.01) and LI (p < 0.01) rats.The effect of D2 receptor antagonism on 5-CSRTT performance is
shown in Fig. 3AeD. Task performance was largely unaffected by
eticlopride treatment; repeated measures ANOVA indicated that
premature responding (Fig. 3A), attentional accuracy (Fig. 3B) and
correct response latencies (Fig. 3D) were no different compared
with vehicle treated controls. This is unlikely due to insufficient
drug exposure given the significant increase in omissions (main
effect of dose, F3,33 ¼ 5.0, p < 0.01) observed at the highest dose
tested (0.02 mg/kg, p < 0.05) (Fig. 3C).
Although eticlopride treatment was without effect when
administered alone, interactive effects with Cpd11 were observed
following co-administration, as shown in Fig. 3EeH. One rat was
excluded from this study due to an error in oral drug administration
(i.e. did not receive full dose). Nevertheless, repeated measures
ANOVA revealed a significant effect of drug treatment on prema-
ture responding (main effect of drug, F2,31 ¼ 5.9, p < 0.01, X2 ¼ 12.4,
Fig. 3. Effects of eticlopride alone (n ¼ 12; A-D) and combined with Cpd11 (n ¼ 16; E-H) on 5-CSRTT performance in MI rats: (A and E) percent premature responses, (B and F)
percent accuracy, (C and G) percent omissions and (D and H) correct response latency. Bars represent mean ± SEM. Repeated measures ANOVA; A-D, Dunnett's post hoc test,
*p < 0.05 verses vehicle control; E-H, Bonferroni post hoc test, *p < 0.05, ***p < 0.001 versus vehicle (labelled ‘Veh-0’), þþp < 0.01 versus Cpd11 alone (labelled ‘Cpd11-0’).
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260 255GG ε ¼ 0.70). Post hoc analysis revealed that Cpd11 evoked an in-
cremental effect on premature responding in the absence of eti-
clopride (p < 0.05), increasing this measure from an average of
9.75 ± 1.3% under the vehicle condition to a maximum of 17 ± 2.5%
following 60 mg/kg Cpd11 administration (Fig. 3E). This behav-
ioural response was dose-dependently attenuated with eticlopride
treatment (0.01 mg/kg, p < 0.01). Furthermore, repeated measures
ANOVA also revealed a significant effect of drug treatment onattentional accuracy (Fig. 3F) (main effect of drug, F3,45 ¼ 6.7,
p < 0.01), but had no effect on omissions (Fig. 3G). Consistent with
the behavioural response to Cpd11 described previously for the
unscreened and HI/LI rats, post hoc analysis revealed that Cpd11
treatment significantly decreased attentional accuracy (p < 0.01).
However, unlike as in the case of premature responding, eticlopride
treatment had no effect on impaired attentional accuracy. Finally,
drug treatment evoked a significant effect on the time taken to
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260256respond correctly (Fig. 3H) (main effect of drug, F3,45 ¼ 8.1,
p < 0.001) and the time required for reward collection (main effect
of drug, F3,45 ¼ 3.6, p < 0.05; data not shown). Post hoc analysis
revealed that whilst alone, Cpd11 treatment had no effect on la-
tencies; co-administration with 0.005 and 0.01 mg/kg eticlopride
treatment significantly increased the latency to respond correctly
compared with the Cpd11-vehicle treated group (p < 0.001 and
p < 0.05, respectively).
3.3. Experiment 2: effect of sub-chronic Cpd11 treatment on 5-
CSRTT performance in MI rats
The performance of MI rats on the 5-CSRTT during sub-chronic
Cpd11 treatment (80 mg/kg) is shown in Fig. 4. The rat groups wereFig. 4. Effect of sub-chronic Cpd11 treatment on 5-CSRTT performance in MI rats (n ¼ 9/
omissions, (D) correct response latency, (E) reward latency and (F) completed trials. Data rep
drug); a priori Bonferroni test, *p < 0.05 versus relative vehicle control.selected based on pre-treatment baseline performance, and
matched for levels of premature responding. There was no signif-
icant difference between groups in any task parameter during the
pre-treatment baseline sessions apart from attentional accuracy.
Although the group to be treatedwith Cpd11 exhibited significantly
higher accuracy (F1,17 ¼ 5.7, p < 0.05), this behavioural profile was
reversed during chronic treatment and lost in the post-treatment
sessions (see below). The pre/post-treatment baseline data were
not included in the statistical analysis of 5-CSRTT performance
during Cpd11 treatment. Overall, the effect of Cpd11 treatment on
5-CSRTT performance was comparable to that described previously
for the unscreened and HI/LI rats; an increase in premature
responding and decrease in attentional accuracy. Repeated mea-
sures ANOVA failed to reveal a significant effect of Cpd11 treatmentor 10 per group): (A) percent premature responses, (B) percent accuracy, (C) percent
resent mean ± SEM. Repeated measures ANOVA, þ p < 0.05, þþ p < 0.01 (main effect of
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260 257on premature responding (F1,17 ¼ 3.17, p ¼ 0.093), nor a significant
drug  day interaction (F4,68 ¼ 1.87, p ¼ 0.13) (Fig. 4A). However, a
planned comparison between vehicle and Cpd11 treated groups
indicated that whilst acute treatment significantly increased pre-
mature responding approximately 3-fold (treatment day 1;
p < 0.05), this behavioural response was lost with subsequent drug
administrations and testing sessions (treatment days 2e5). In
contrast, Cpd11 treatment significantly decreased attentional ac-
curacy in the 5-CSRTT (main effect of drug, F1,17 ¼ 12.8, p < 0.01).
This effect was maintained throughout the five days of Cpd11
treatment, as shown by a lack of drug  day interaction, decreasing
accuracy by approximately 10% on each test session (Fig. 4B). To
investigate whether chronic Cpd11 treatment resulted in long-
lasting effects on attentional accuracy, data from two post-
treatment test sessions were analysed. No significant difference
in attentional performance was observed between groups in either
post-treatment test session. Consistent with the behavioural profile
evoked by acute Cpd11 administration observed earlier, Cpd11 had
no effect on any other task parameter (Fig. 4CeF).3.4. Experiment 3: effect of positive allosteric mGluR4 modulation
on DDT performance
The effect of Cpd11 treatment on DDT performance is shown in
Fig. 5. As the delay to the large-magnitude reward increased, the
choice for that reward decreased (main effect of delay, F2,29 ¼ 89.2,
p < 0.001, X2¼112.5, GG ε¼ 0.41). This effect was dependent on the
drug dose, as demonstrated by a significant delay  dose interac-
tion (F15,210 ¼ 1.7, p < 0.05). Post hoc analysis revealed that Cpd11
increased preference for the delayed reward under the 2 s delay
(40 mg/kg, p < 0.01; 60 mg/kg, p < 0.001; 80 mg/kg, p < 0.01).
However, it should be noted that under the vehicle condition,
preference for the delayed reward dropped to as low as 25% at the
2 s delay. Used as a positive control, and analysed separately, d-
amphetamine administration (0.5 mg/kg) significantly increased
the preference for the larger delayed reward. This effect occurred in
a delay dependent manner, as indicated by a significant
drug  delay interaction (F3,38 ¼ 12.3, p < 0.001, X2 ¼ 33.8, GG
ε ¼ 0.54). Thus, d-amphetamine increased choice for the large
delayed reward when the delay to the reward was 2 and 4 s long
(p < 0.001), but decreased preference for the large reward, when
there was no delay (p < 0.01).Fig. 5. Effect of Cpd11 on delay discounting performance (80 mg/kg; n ¼ 15). Data
represent mean ± SEM percent choice for the delayed reward. Repeated measures
ANOVA, Fisher's LSD post hoc test, Cpd11 40 mg/kg, p < 0.01; 60 mg/kg, p < 0.001;
80 mg/kg, p < 0.01 verses vehicle control (significance levels not shown), **p < 0.01,
***p < 0.001 d-amphetamine versus vehicle control.3.5. Experiment 4: effect of positive allosteric mGluR4 modulation
on locomotor activity
The effect of positive allosteric mGluR4modulation, by systemic
Cpd11 administration, on locomotor activity is shown in Table 3.
Cpd11 treatment produced significant effects on all behavioural
measures of motor activity, including rearing time (F3,28 ¼ 37.0,
p < 0.001), rearing sum (F3,28 ¼ 14.4, p < 0.001) and distance
travelled (F3,28 ¼ 3.0, p < 0.05). Whereas total rearing and the time
spent rearing were significantly reduced by all doses of Cpd11
(sum: 40 and 60 mg/kg, p < 0.01, 80 mg/kg, p < 0.001; time:
40e80 mg/kg, p < 0.001), the distance travelled was unaffected by
the lower doses (40 and 60mg/kg). In contrast Cpd11, administered
at a dose of 80 mg/kg, significantly decreased total distance trav-
elled (p < 0.05).
4. Discussion
This study investigated the role of mGluR4 in modulating two
distinct forms of waiting impulsivity and its putative interaction
with D2 receptors in modulating motor impulsivity on the 5-CSRTT.
The main findings indicate a prominent role of mGluR4 in modu-
lating motor, and to some extent choice, impulsivity as well as as-
pects of visual attention. Specifically, Cpd11 increased premature
responding and decreased attentional accuracy on the 5-CSRTT, an
effect that was independent of impulsivity sub-group. Furthermore,
the data provide support for an involvement of D2 receptor-
expressing indirect pathway in mediating this behavioural
response. Thus D2 receptor antagonism by eticlopride significantly
attenuated the effect of Cpd11 on premature responding, but was
without effect when administered alone. By contrast, Cpd11
decreased choice impulsivity, increasing preference for the large-
magnitude, delayed reward.
Although the neural mechanism responsible for the observed
increase in motor impulsivity is unclear, it may involve the indirect
pathway within the basal ganglia. In rodents the striatum is the
primary input nucleus of the basal ganglia, receiving glutamatergic
input from the cortex, and extending GABA-ergic projections
directly to the output nuclei and indirectly via the pallidum and
STN (Albin et al., 1989; DeLong, 1990). It is well established that
mGluR4s are discretely expressed pre-synaptically within the
striatum and pallidum, specifically within cortico-striatal and
striato-pallidal glutamatergic and GABA-ergic projections, respec-
tively (Bennouar et al., 2013; Beurrier et al., 2009; Bradley et al.,
1999; Corti et al., 2002; Cuomo et al., 2009; Gubellini et al.,
2014). Thus mGluR4s are ideally located to modulate neurotrans-
mission within this circuitry, primarily by suppressing neuro-
transmitter release. By contrast, mGluR4 is only weakly expressed
within the direct pathway (Bradley et al., 1999). Based on these
findings, it was hypothesised that positive allosteric mGluR4
modulation evoked the observed behavioural effects by suppress-
ing cortico-striatal or striato-pallidal neurotransmission. In either
case, this would result in increased activity of the pallidum throughTable 3
Effect of Cpd11 (40e80 mg/kg, p.o.) on locomotor activity: rearing time (sec), total
rearing (sum) and distance travelled (cm).
Cpd11 (mg/kg) Rearing time (sec) Rearing (sum) Distance (cm)
0 375.9 ± 21.55 125.0 ± 5.42 4141 ± 323.2
40 174.8 ± 22.37 *** 84.25 ± 10.65 ** 3424 ± 333.0
60 175.4 ± 19.59 *** 86.25 ± 7.20 ** 3453 ± 208.5
80 91.19 ± 15.32 *** 50.75 ± 7.83 *** 2883 ± 309.6 *
Values represent mean ± SEM (n ¼ 8 per group). One-way ANOVA, Dunnett's post
hoc test, *p < 0.05, **p < 0.01, ***p < 0.001 verses vehicle control.
S.N. Isherwood et al. / Neuropharmacology 123 (2017) 249e260258disinhibition (see Fig. 6 for summary). Studies in brain slices appear
to support this hypothesis; electrical stimulation of striatal or GP
afferents evokes glutamate-mediated EPSCs and GABA-mediated
IPSCs within the respective brain regions. Such evoked potentials
are dose-dependently attenuated by the application of mGluR4
agonists (Beurrier et al., 2009; Cuomo et al., 2009; Gubellini et al.,
2014; Marino et al., 2003; Pisani et al., 1997; Valenti et al., 2003).
It is also noteworthy that the effect of Cpd11 on motor impulsivity
was paralleled by a decrease in locomotor activity, confirming that
the increase in premature responding was not simply a conse-
quence of drug-induced hyperactivity.
We also investigated the cooperative role of mGluR4 and D2
receptor modulation on 5-CSRTT performance. It was hypothesised
that pharmacological blockade of D2 receptors would counteract
the effect of mGluR4 activation (see Fig. 6 for summary). We found
that D2 receptor antagonism by systemic eticlopride administration
dose-dependently attenuated the effects of Cpd11 on premature
responding but failed to improve disruptive effects of Cpd11 on
attention, indicating that the origin of premature responding is
dissociable from attentional deficits. Importantly, systemic eti-
clopride treatment, up to a dose of 0.03 mg/kg (although i.p.), has
no effect on spontaneous locomotor activity (Schindler and
Carmona, 2002) thus indicating a selective reduction in impul-
sivity by D2 receptor antagonism. Moreover, eticlopride treatment
had no effect on premature responding when administered alone
nor did it modulate any other task parameter, apart from omissions
at the highest dose tested (0.02 mg/kg) (Pattij et al., 2007; van
Gaalen et al., 2006). Such a behavioural profile reflects the suit-
ability of the selected dose range when administered subcutane-
ously; the increase in omitted trials is likely to reflect non-selective
motoric effects of the drug at this dose. Together, these findings
suggest that the effect of Cpd11 on motor impulsivity is subject to
modulation by D2 receptor antagonism. Further experiments are
needed, however, to identify the neural loci responsible for medi-
ating this interaction.
Several lines of evidence suggest that Cpd11 may exert its
behavioural effect on 5-CSRTT impulsivity by suppressing GABA-
ergic neurotransmission. Local GP infusion of the mGluR4 agonistFig. 6. Schematic diagram summarising the hypothesised involvement of the direct and indi
antagonism on striatal, pallidal and subthalamic activity. The diagram shows that positive
pallidal GABAergic neurotransmission, leading to pallidal disinhibition and subsequently ST
ergic neurotransmission, leading to pallidal inhibition and subsequently STN disinhibitionLSP1-2111 has been shown to increase premature responding on a
reaction time task (Beurrier et al., 2009). Moreover, blocking GABA-
ergic neurotransmission post-synaptically produced a similar effect
(Lopez et al., 2007). Whether mGluR4 activation within the ventral
division of this circuitry produces a similar effect has not yet been
investigated. However, it should be noted that the action of allo-
steric modulators, such as Cpd11, is restricted to endogenously
active receptors. This is important since the striato-pallidal synapse
is GABA-ergic where the basal levels of glutamate are likely low and
may be insufficient to sustain mGluR4 activation for allosteric
modulation. Indeed, positive allosteric mGluR4 modulation fails to
inhibit striato-pallidal neurotransmission in vitro (Gubellini et al.,
2014; Marino et al., 2003). Increasing glutamate concentration by
applying TBAO, a broad-spectrum glutamate transporter blocker,
enabled positive allosteric mGluR4 modulation to show efficacy
(Gubellini et al., 2014). Since the GP receives glutamatergic input
from the STN (Parent and Hazrati, 1995), it is predicted that this
may provide sufficient levels of glutamate within the striato-
pallidal synapse for allosteric efficacy in vivo (Marino et al., 2003).
By contrast, the cortico-striatal synapse is glutamatergic, where
sufficient levels of glutamate are likely present. Additional studies
are required to determine which neural mechanism prevails.
Neurally, it is currently unknown how suppression of cortico-
striatal or striato-pallidal neurotransmission might mediate the
observed increase in motor impulsivity. Recent evidence suggests
that the STN may play a significant role (Baunez et al., 2001; Florio
et al., 2001; Phillips and Brown, 2000; Phillips and Brown, 1999).
Indeed, bilateral lesions to the STN as well as pharmacological
inactivation increases premature responding and decreases atten-
tional accuracy on the 5-CSRTT (Baunez and Robbins, 1997, 1995).
Thus, positive allosteric mGluR4 modulation is hypothesised to
increase pallidal activity and subsequently reduce STN activity
(Beurrier et al., 2009; Cuomo et al., 2009; Gubellini et al., 2014).
Consistent with this hypothesis, the dopamine receptor antagonist
a-flupenthixol has been shown to selectively attenuate the effect of
STN lesions on premature responding (Baunez and Robbins, 1997).
Sub-chronic administration of Cpd11 acutely increased prema-
ture responding on the first challenge day but failed to evoke thisrect pathways and the effects of positive allosteric mGluR4 modulation and D2 receptor
allosteric mGluR4 modulation suppresses cortico-striatal glutamatergic and/or striato-
N inhibition (A). By contrast, D2 receptor antagonism increases striato-pallidal GABA-
(B).
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magnitude of increase in premature responding on day 1 was
comparable to that observed in the earlier experiments. In contrast,
the effect of Cpd11 administration on attentional accuracy was
consistently maintained throughout drug treatment and recovered
to pre-drug levels following drug discontinuation. This dissociation
highlights a separation in neural mechanisms mediating impulse
control and attentional accuracy in the 5-CSRTT (Robbins, 2002)
and tends to rule out the possibility that the decline in effect of
Cpd11 on premature responding was due to mGluR4
desensitisation.
Whilst systemic Cpd11 administration increased motor impul-
sivity, the same compound decreased choice impulsivity in the
DDT. Although the task was sufficiently sensitive to detect the ex-
pected impulsivity-reducing effects of d-amphetamine, the
conclusion that Cpd11 reduces choice impulsivity requires repli-
cation as control animals appeared to show an unexpectedly steep
rate of discounting at 2 s. Indeed in our recent study preference for
the delayed reward was higher in control rats at this delay
(Isherwood et al., 2015). Nevertheless, the apparently opposing
effect of Cpd11 on motor and choice impulsivity is consistent with
studies demonstrating that lesions of the STN produce similarly
opposing effects on motor and choice impulsivity (Baunez and
Robbins, 1997; Uslaner and Robinson, 2006; Winstanley et al.,
2005). Furthermore, the profile of effects of Cpd11 on motor and
choice impulsivity is consistent with a common effect on waiting
impulsivity, which may involve impairments in response inhibition
and/or temporal perception (Cope et al., 2016; Evenden, 1999).
Indeed, we cannot fully exclude the possibility that increased pre-
mature responding resulting from Cpd11 administration might
reflect an independent deficit in the perception of wait time, and
lost opportunity to respond for reward, rather than an effect on
response inhibition.
In summary, we have demonstrated that mGluR4 and D2 re-
ceptors play a cooperative role in the regulation and inhibitory
control of behaviour. In particular, Cpd11 increased premature
responding and decreased attentional accuracy whilst apparently
also reducing choice impulsivity. D2 receptor antagonism attenu-
ated the effect of Cpd11 on premature responding, but had no effect
on the attentional deficits incurred. These findings implicate an
involvement of the D2 receptor-expressing indirect striato-pallidal-
sub-thalamic pathway in mediating the effects of positive allosteric
mGluR4 modulation on impulsivity. Together, these findings
enhance our understanding of the neurobiological substrates un-
derpinning impulsivity and suggest that mGluR4 may be a novel
target to treat specific aspects of maladaptive impulsivity.
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